Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
JCO Oncology Practice|October 31, 2024
Willingness of Women at Increased Risk of Breast Cancer to Participate in Prevention TrialsCecilia N Mastrogiacomo, Alexa Courtepatte, Anne Moyer, et al.
Journal of Medical Economics|August 1, 2019
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United StatesAlison Stopeck, Adam Brufsky, Lisa Kennedy, et al.
Journal of Women'S Health (2002)|January 5, 2010
Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapyCynthia A Thomson, Patricia A Thompson, Jennifer Wright-Bea, et al.
Journal of Medical Economics|March 14, 2012
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United StatesAlison Stopeck, Michael Rader, David Henry, et al.
International Journal of Radiation Oncology, Biology, Physics|October 4, 2023
Utility of Stereotactic Body Radiation Therapy in Establishing Local Control for Patients With Invasive Breast Cancer Not Undergoing Definitive SurgeryEwa Zabrocka, Simran Polce, John D Roberson, et al.
Patient Preference and Adherence|September 17, 2013
Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastasesLouis S Matza, Ze Cong, Karen Chung, et al.
Journal of Bone Oncology|March 4, 2022
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approvalBenoit Cadieux, Robert Coleman, Pegah Jafarinasabian, et al.
Neoplasia (New York, N.Y.)|February 22, 2005
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapyRebecca J Theilmann, Rebecca Borders, Theodore P Trouard, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 19, 2025
Factors associated with avoidable 30-day readmissions in patients with cancer: a single institution studyMonica E Raiss, Krisha K Mehta, Xiaoyue Zhang, et al.
Clinical Breast Cancer|November 14, 2018
Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast CancerPeter A Kaufman, Hans Wildiers, Gilles Freyer, et al.
Pageof 4